(Q26852311)

language of work or name

1 reference

2014

1 reference

published in

Frontiers in Neurology

1 reference

volume

5

1 reference

page(s)

144

1 reference

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction

7 April 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Metabotropic glutamate receptors in the basal ganglia motor circuit

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Pharmacology and functions of metabotropic glutamate receptors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Advances in non-dopaminergic treatments for Parkinson's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Modeling dyskinesia in animal models of Parkinson disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Priorities in Parkinson's disease research

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Metabotropic glutamate receptors: physiology, pharmacology, and disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Glutamate receptors as therapeutic targets for Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The scientific and clinical basis for the treatment of Parkinson disease (2009).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Treatment of levodopa-induced motor complications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Molecular mechanisms of L-DOPA-induced dyskinesia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Progress in Parkinson's disease-where do we stand?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Association between AKT1 gene and Parkinson's disease: a protective haplotype

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Levodopa-induced dyskinesias

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The Akt-GSK-3 signaling cascade in the actions of dopamine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Role of the ERK pathway in psychostimulant-induced locomotor sensitization.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Levodopa and the progression of Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Update on Parkinson disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

The neurobiology of slow synaptic transmission

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Kynurenines in the CNS: from endogenous obscurity to therapeutic importance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Wnt factors in axonal remodelling and synaptogenesis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Metabotropic glutamate receptors for Parkinson's disease therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

MAP kinase-dependent pathways in cell cycle control.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Dopamine D2 receptor density remains constant in treated Parkinson's disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

31 May 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Metabotropic glutamate receptor II in the brains of Parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2014.00144

Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4122180

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

28 November 2018

1 reference

12 December 2020

Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats

1 reference

12 December 2020

Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis

1 reference

12 December 2020

Functional neurochemistry of the basal ganglia

1 reference

12 December 2020

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys

1 reference

12 December 2020

Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia

1 reference

12 December 2020

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys

1 reference

12 December 2020

[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy

1 reference

12 December 2020

Glutamate release inhibition ineffective in levodopa-induced motor complications

1 reference

12 December 2020

Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys

1 reference

12 December 2020

Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias

1 reference

12 December 2020

Levodopa-induced dopamine receptor hypersensitivity

1 reference

12 December 2020